Study of urinary proteomes in Anderson-Fabry disease

REFERENCES

• Beck M, Ricci R, Widmer U, Fabry disease: Overall effects of agalsidase alfa treatment. Eur J Clin Invest. 2004;34:838–844.
   PubMed Web of Science ®Google Scholar
• Mehta A, Ricci R, Widmer U, Fabry disease defined: Baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004;34:236–242.
   PubMed Web of Science ®Google Scholar
• Elleder M. Sequelae of storage in Fabry disease – pathology and comparison with other lysosomal storage diseases. Acta Paediatr Suppl. 2003;92:46–53.
   PubMedGoogle Scholar
• Linhart A, Palecek T, Bultas J, New insights in cardiac structural changes in patients with Fabry's disease. Am Heart J. 2000;139:1101–1108.
   PubMedGoogle Scholar
• Linhart A, Elliott PM. The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart. 2007;93:528–535.
   PubMedGoogle Scholar
• Tesar V, Zima T, Kalousová M. Pathobiochemistry of nephrotic syndrome. Adv Clin Chem. 2003;37:173–218.
   PubMedGoogle Scholar
• Schiffmann R, Murray GJ, Treco D, Infusion of α-galactosidase A reduces tissue globotriaozylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA. 2000;97:365–370.
   PubMed Web of Science ®Google Scholar
• Spada M, Pagliardini S, Yasuda M, High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79:31–40.
   PubMed Web of Science ®Google Scholar
• MecDermot J, Holmes A, Miners A. Anderson-Fabry disease: Clinical manifestations in a cohort of 60 obligate carrier females. J Med Genet. 2001;38:769–775.
   PubMedGoogle Scholar
• Eng CM, Guffon N, Wilcox WR, Safety and efficacy of recombinant human α-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med. 2001;345:9–16.
   PubMed Web of Science ®Google Scholar
• Schiffmann R, Kopp JB, Austin HA. Enzyme replacement therapy in Fabry disease: A randomized controlled trial. J Am Med Assoc. 2001;285:2743–2749.
   PubMed Web of Science ®Google Scholar
• Banikazemi M, Bultas J, Waldek S, Agalsidase-beta therapy for advanced Fabry disease: A randomized trial. Ann Intern Med. 2007;146:77–86.
   PubMed Web of Science ®Google Scholar
• Aerts JM, Groener JE, Kuiper S, Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA. 2008;105(8):2812–2817.
   PubMed Web of Science ®Google Scholar
• Schiffmann R, Waldek S, Benigni A, Auray-Blais Ch. Biomarkers of Fabry disease nephropathy. Clin J Am Soc Nephrol. 2010;5(2):360–364.
   PubMed Web of Science ®Google Scholar
• Vojtová L, Zima T, Tesar V, Kazderová M. Study of urinary proteomes in patients with nephrotic syndrome. Folia Biol (Praha). 2007;53(2):58–65.
   PubMedGoogle Scholar
• Cutillas PR, Chalkley RJ, Hansen KC, The urinary proteome in Fanconi syndrome implies specificity in the reabsorption of proteins by renal proximal tubule cells. Am J Physiol Renal Physiol. 2004;287:F353–F364.
   PubMed Web of Science ®Google Scholar
• Pieper R, Gatlin ChL, McGrath AM. Characterization of the human urinary proteome A method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics. 2004;4:1159–1174.
   PubMed Web of Science ®Google Scholar
• Rossing K, Mischak H, Parving H-H. Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. Kidney Int. 2005;68:193–205.
   PubMed Web of Science ®Google Scholar
• Joo W-A, Lee D-Y, Kim Ch-W. Development of an effective sample preparation method for the proteome analysis of body fluids using 2-D gel electrophoresis. Biosci Biotechnol Bioc hem. 2003;67:1574–1577.
   PubMed Web of Science ®Google Scholar
• Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248.
   PubMed Web of Science ®Google Scholar
• Watanabe N, Kamei S, Ohkubo A. Urinary protein as measured with a pyrogallol red-molybdate complex, manually and in a Hitachi 726 automated analyzer. Clin Chem. 1986;32: 1551–1554.
   PubMed Web of Science ®Google Scholar
• Kleinbaum DG, Kupper CL, Muller KF. Applied Regression Analysis and Other Multivariable Methods. Boston: PWS-Kent; 1988.
   Google Scholar
• Dean KJ, Sung SS, Sweeley CC. The identification of alpha-galactosidase B from human liver as an alpha-N-acetylgalactosaminidase. Biochem Biophys Res Commun. 1977;77(4):1411–1417.
   PubMedGoogle Scholar
• Ogawa M, Hirawa N, Tsuchida T. Urinary excretions of lipocalin-type prostaglandin D2 synthase predict the development of proteinuria and renal injury in OLETF rats. Nephrol Dial Transplant. 2005;21:924–934.
   PubMedGoogle Scholar
• Oda H, Shiina Y, Seiki K. Development and evaluation of a practical ELISA for human urinary lipocalin-type prostaglandin D synthase. Clin Chem. 2002;48:1445–1453.
   PubMed Web of Science ®Google Scholar
• Tsuchida T, Eguchi N, Eguchi Y. Lipocalin-type prostaglandin D synthase in urine in adriamycin-induced nephropathy of mice. Nephrol Physiol. 2004;96:42–51.
   Google Scholar
• Tesar V, Zima T. Recent progress in pathogenesis of nephrotic proteinuria. Crit Rev Clin Lab Sci. 2008;45:139–220.
   PubMed Web of Science ®Google Scholar
• Haraldsson B, Nystrom J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev. 2008;88:451–487.
   PubMed Web of Science ®Google Scholar
• Vilasi A, Cutillas PR, Maher AD. Combined proteomic and metabonomic studies in three genetic forms of the renal Fanconi syndrome. Am J Physiol Renal Physiol. 2007;293:456–467.
   PubMed Web of Science ®Google Scholar
• Utsumi K, Itoh K, Kase R. Urinary excretion of the vitronectin receptor (integrin αVβ3) in patients with Fabry disease. Clin Chem Acta. 1999;279:55–68.
   PubMedGoogle Scholar
• Moran V, Obrador GT, Thandahi R. Fabry kidney disease. Saudi J Kidney Dis Transpl. 2003;14(1):367–377.
   PubMedGoogle Scholar
• Ortiz A, Oliviera JP, Waldek S. Nephropathy in males and females with Fabry disease: Cross-sectional description of patients before treatment with enzymereplacement therapy. Nephrol Dial Transplant. 2008;23:1600–1607.
   PubMed Web of Science ®Google Scholar